A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases the risk of papillary thyroid carcinoma

Genetic Testing and Molecular Biomarkers

Volumn 19, Issue 3, 2015, Pages 167-171

  Wang, Xunli ^a   Peng, Hong ^b   Liang, Yundan ^c   Sun, Ruifen ^c   Wei, Tao ^a   Li, Zhihui ^a   Gong, Yanping ^a   Gong, Rixiang ^a   Liu, Feng ^a   Zhang, Lin ^c,d   Zhu, Jingqiang ^a  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c SICHUAN UNIVERSITY   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NFKB1 PROTEIN; UNCLASSIFIED DRUG; NFKB1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RISK; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PROMOTER REGION; THYROID CARCINOMA; CARCINOMA; CASE CONTROL STUDY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK FACTOR; THYROID TUMOR;

CARCINOMA; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDEL MUTATION; MALE; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; PROMOTER REGIONS, GENETIC; RISK FACTORS; THYROID NEOPLASMS;

EID: 84924369955     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2014.0271     Document Type: Article

References (54)

1. Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203-208.
2. Aggarwal BB, Shishodia S, Takada Y, et al. (2005) Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11:7490-7498.
3. Baldwin AS (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107:241-246.
4. Bu H, Rosdahl I, Sun XF, et al. (2007) Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol 133:859-866.
5. Cai H, Sun L, Cui L, et al. (2013) A functional insertion/deletion polymorphism ( - 94 ins/del ATTG) in the promoter region of the NFKB1 gene is related to the risk of renal cell carcinoma. Urol Int 91:206-212.
6. Caron NR, Clark OH (2006) Papillary thyroid cancer. Curr Treat Options Oncol 7:309-319.
7. Cheng CW, Su JL, Lin CW, et al. (2013) Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features. PLoS One 8:e56130.
8. Dardano A, Falzoni S, Caraccio N, et al. (2009) 1513A >C polymorphism in the P2X7 receptor gene in patients with papillary thyroid cancer: correlation with histological variants and clinical parameters. J Clin Endocrinol Metab 94:695-698.
9. Duan W, Wang E, Zhang F, et al. (2014) Association between the NFKB1-94 ins/del ATTG polymorphism and cancer risk: an updated meta-Analysis. Cancer Invest 32:311-320.
10. Elsharkawy AM, Oakley F, Lin F, et al. (2010) The NF-kappaB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes. J Hepatol 53:519-527.
11. Fan Y, Yu W, Ye P, et al. (2011) NFKB1 insertion/deletion promoter polymorphism increases the risk of advanced ovarian cancer in a Chinese population. DNA Cell Biol 30: 241-245.
12. Ghosh S, May MJ, Kopp EB (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260.
13. Gimm O (2001) Thyroid cancer. Cancer Lett 163:143-156.
14. Giordano TJ, Kuick R, Thomas DG, et al. (2005) Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24: 6646-6656.
15. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. (2009) Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet 41:460-464.
16. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. (2012) Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet 44:319-322.
17. Guigon CJ, Zhao L, Willingham MC, et al. (2009) PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 28:509-517.
18. He H, Nagy R, Liyanarachchi S, et al. (2009) A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Res 69:625-631.
19. Huang D, Yang L, Liu Y, et al. (2013) Functional polymorphisms in NFkappaB1/IkappaBalpha predict risks of chronic obstructive pulmonary disease and lung cancer in Chinese. Hum Genet 132:451-460.
20. Jazdzewski K, Liyanarachchi S, Swierniak M, et al. (2009) Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A 106:1502-1505.
21. Jendrzejewski J, He H, Radomska HS, et al. (2012) The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci U S A 109:8646-8651.
22. Jones AM, Howarth KM, Martin L, et al. (2012) Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24. J Med Genet 49:158-163.
23. Karban AS, Okazaki T, Panhuysen CI, et al. (2004) Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 13:35-45.
24. Kato Y, Ying H, Zhao L, et al. (2006) PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 25:2736-2747.
25. Kilfoy BA, Zheng T, Holford TR, et al. (2009) International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20:525-531.
26. Kohler A, Chen B, Gemignani F, et al. (2013) Genome-wide association study on differentiated thyroid cancer. J Clin Endocrinol Metab 98:E1674-E1681.
27. Kouniavsky G, Zeiger MA (2010) Thyroid tumorigenesis and molecular markers in thyroid cancer. Curr Opin Oncol 22: 23-29.
28. Lewander A, Butchi AK, Gao J, et al. (2007) Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol 42:1332-1338.
29. Li P, Gu J, Yang X, et al. (2013) Functional promoter - 94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population. PLoS One 8: e71604.
30. Li Y, Ahmed F, Ali S, et al. (2005) Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65:6934-6942.
31. Lin SC, Liu CJ, Yeh WI, et al. (2006) Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett 243:47-54.
32. Lo SS, Chen JH, Wu CW, et al. (2009) Functional polymorphism of NFKB1 promoter may correlate to the susceptibility of gastric cancer in aged patients. Surgery 145:280-285.
33. Mohd Suzairi MS, Tan SC, Ahmad Aizat AA, et al. (2013) The functional - 94 insertion/deletion ATTG polymorphism in the promoter region of NFKB1 gene increases the risk of sporadic colorectal cancer. Cancer Epidemiol 37:634-638.
34. Pacifico F, Leonardi A (2010) Role of NF-kappaB in thyroid cancer. Mol Cell Endocrinol 321:29-35.
35. Pacifico F, Mauro C, Barone C, et al. (2004) Oncogenic and anti-Apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 279:54610-54619.
36. Palona I, Namba H, Mitsutake N, et al. (2006) BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 147:5699-5707.
37. Riemann K, Becker L, Struwe H, et al. (2006) No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. Pharmacogenet Genomics 16:783-788.
38. Riemann K, Becker L, Struwe H, et al. (2007) Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther 45:423-430.
39. Ron E, Lubin JH, Shore RE, et al. (1995) Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141:259-277.
40. Shih VF, Tsui R, Caldwell A, et al. (2011) A single NFkappaB system for both canonical and non-canonical signaling. Cell Res 21:86-102.
41. Song S, Chen D, Lu J, et al. (2011) NFkappaB1 and NFkappaBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population. PLoS One 6:e21726.
42. Starenki DV, Namba H, Saenko VA, et al. (2004) Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res 10:6821-6829.
43. Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107:7-11.
44. Takahashi M, Saenko VA, Rogounovitch TI, et al. (2010) The FOXE1 locus is a major genetic determinant for radiationrelated thyroid carcinoma in Chernobyl. Hum Mol Genet 19:2516-2523.
45. Tang T, Cui S, Deng X, et al. (2010) Insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for superficial bladder cancer in Chinese. DNA Cell Biol 29:9-12.
46. Vallabhapurapu S, Karin M (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27:693-733.
47. Vasudevan KM, Gurumurthy S, Rangnekar VM (2004) Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 24:1007-1021.
48. Visconti R, Cerutti J, Battista S, et al. (1997) Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 15: 1987-1994.
49. Xu L, Huang S, Chen W, et al. (2014) NFKB1-94 insertion/deletion polymorphism and cancer risk: a meta-Analysis. Tumour Biol 35:5181-5187.
50. Yang CH, Murti A, Pfeffer LM (2005) Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptorassociated factor-dependent NF-kappa B activation to promote cell survival. J Biol Chem 280:31530-31536.
51. Yu Y, Wan Y, Huang C (2009) The biological functions of NFkappaB1 (p50) and its potential as an anti-cancer target. Curr Cancer Drug Targets 9:566-571.
52. Zhang P, Wei Q, Li X, et al. (2009) A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer. Cancer Genet Cytogenet 191:73-77.
53. Zhou B, Qie M, Wang Y, et al. (2010) Relationship between NFKB1-94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk. Ann Oncol 21:506-511.
54. Zhou B, Rao L, Li Y, et al. (2009) A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Lett 275:72-76.